- Home
- BHRB vs MYGN Comparison
BHRB vs MYGN Comparison
Compare BHRB & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHRB
- MYGN
- Stock Information
- Founded
- BHRB 1852
- MYGN 1991
- Country
- BHRB United States
- MYGN United States
- Employees
- BHRB N/A
- MYGN N/A
- Industry
- BHRB Major Banks
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- BHRB Finance
- MYGN Health Care
- Exchange
- BHRB Nasdaq
- MYGN Nasdaq
- Market Cap
- BHRB 940.0M
- MYGN 756.5M
- IPO Year
- BHRB N/A
- MYGN 1995
- Fundamental
- Price
- BHRB $58.86
- MYGN $8.04
- Analyst Decision
- BHRB Strong Buy
- MYGN Hold
- Analyst Count
- BHRB 3
- MYGN 13
- Target Price
- BHRB $71.67
- MYGN $13.50
- AVG Volume (30 Days)
- BHRB 43.3K
- MYGN 901.6K
- Earning Date
- BHRB 10-23-2025
- MYGN 11-03-2025
- Dividend Yield
- BHRB 3.74%
- MYGN N/A
- EPS Growth
- BHRB 337.34
- MYGN N/A
- EPS
- BHRB 8.48
- MYGN N/A
- Revenue
- BHRB $331,053,000.00
- MYGN $832,900,000.00
- Revenue This Year
- BHRB $51.36
- MYGN $0.06
- Revenue Next Year
- BHRB $5.03
- MYGN $5.68
- P/E Ratio
- BHRB $6.94
- MYGN N/A
- Revenue Growth
- BHRB 82.52
- MYGN 3.83
- 52 Week Low
- BHRB $47.57
- MYGN $3.76
- 52 Week High
- BHRB $75.32
- MYGN $22.81
- Technical
- Relative Strength Index (RSI)
- BHRB 42.15
- MYGN 57.57
- Support Level
- BHRB $57.42
- MYGN $7.76
- Resistance Level
- BHRB $61.86
- MYGN $8.18
- Average True Range (ATR)
- BHRB 1.60
- MYGN 0.37
- MACD
- BHRB -0.03
- MYGN -0.03
- Stochastic Oscillator
- BHRB 27.91
- MYGN 43.59
About BHRB Burke & Herbert Financial Services Corp.
Burke & Herbert Financial Services Corp is the bank holding company. Through its subsidiary, it predominantly serves small to medium-sized businesses, their owners and employees, professional corporations, non-profits, and individuals with various banking products and financial services. Some of its products and service offerings include checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential mortgage, acquisition, construction, and development loans, online banking, mobile banking, and wealth and trust services. The company operates in a single segment, namely Community Banking.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.